Gatralimab Biosimilar - Research Grade

Human

CD52

>1mg/ml

IgG1 - kappa

CHO Cells

Alemtuzumab Biosimilar - Research Grade (ICH4002), Tamtuvetmab Biosimilar - Research Grade (ICH5899)

https://www.imgt.org/mAb-DB/

ICH3002

P31358

1043

Blue ice

This product is an unconjugated, non-therapeutic recombinant analog of the anti-CD52 antibody gatralimab, produced for research use only. It reproduces the human IgG1/kappa framework and CD52-directed binding of the originator biologic but is not the clinical drug and is not intended for human or veterinary use. Because CD52 is a target exploited by lymphocyte-depleting antibodies, a bench-scale analog is useful as a defined, consistent reagent for in-vitro binding characterization, epitope and cross-reactivity studies, ADCC and complement-dependent cytotoxicity assay development, and as a positive or isotype-matched control alongside other anti-CD52 tools. It is supplied at research grade with low endotoxin (typically under 1 EU/mg, with an ultra-low sub-0.5 EU/mg option) and is available in bulk milligram-to-gram quantities to support assay standardization, reproducibility across lots, and preclinical model work. Researchers commonly use such analogs to benchmark potency, support antibody-engineering and ADC-development pipelines, and generate comparator data without sourcing scarce or costly clinical material. CD52 (encoded by the CD52 gene; UniProt P31358) is a very small glycoprotein consisting of a short 12-amino-acid mature peptide anchored to the cell surface by a glycosylphosphatidylinositol (GPI) linkage and decorated with a large N-linked glycan. It is expressed abundantly on the surface of most mature lymphocytes, including T cells, B cells, natural killer cells, monocytes, macrophages, dendritic cells, and cells of the male reproductive tract, but is notably absent from hematopoietic stem cells. Despite its small size, CD52 is displayed at high copy number, making it an efficient target for antibody-mediated lysis via complement-dependent cytotoxicity and antibody-dependent cell-mediated cytotoxicity. Its precise physiological function is incompletely defined, though roles in T-cell costimulation, immune regulation, and modulation of complement have been proposed. Its broad lymphocyte expression underlies interest in CD52 as a target for profound, durable lymphocyte depletion.

Campath-1 antigen, Cambridge pathology 1 antigen, HE5

This monoclonal antibody was purified using Protein A

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

3-4 weeks

Gatralimab (anti-CD52) Biosimilar

Q: Is the Gatralimab biosimilar available in bulk or gram quantities?

A: Yes — the Gatralimab biosimilar is manufactured in scalable milligram to gram quantities to support high-throughput and heavy-usage laboratories.

Q: Is this research-grade Gatralimab suitable for in vivo studies?

A: Yes, it is a low-endotoxin, in vivo-ready formulation intended for preclinical and in vivo research use only (RUO).

Q: What does the Gatralimab biosimilar target?

A: It is an unconjugated, non-therapeutic analog of Gatralimab that binds CD52.